Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Double-Blinded Comparison Study Using TXA127 and/or Neupogen to Increase Peripheral Blood Stem Cell (CD34+) Counts

NCT01543971 is registered in ClinicalTrials.gov with Tarix Pharmaceuticals as lead sponsor.

NCT NCT01543971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01543971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Double-Blinded Comparison Study Using TXA127 and/or Neupogen to Increase Peripheral Blood Stem Cell (CD34+) Counts
Lead sponsor
Tarix Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2009
Completion date
March 31, 2010
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

miscellaneous peripheral blood cell abnormalities